2009
Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy
Choueiri T, Xie W, D'Amico A, Ross R, Hu J, Pomerantz M, Regan M, Taplin M, Kantoff P, Sartor O, Oh W. Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy. Cancer 2009, 115: 981-987. PMID: 19152438, PMCID: PMC2931827, DOI: 10.1002/cncr.24064.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapy initiationProstate-specific antigen nadirHormone-sensitive prostate cancerMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyProstate-specific antigenInitiation of androgen deprivation therapyTreated with androgen deprivation therapyGleason score >7Overall survivalPSA declineShorter OSProstate cancerKinetics of prostate-specific antigenResponse to ADTNadir prostate-specific antigenProstate-specific antigen declineAssociated with shorter OSAssociated with shorter survival durationMedian PSA levelSerum PSA valuesSerum PSA determinationMedian Follow-UpAuthors' institutional databaseShorter survival duration
1997
Evaluating neoadjuvant therapy effectiveness on systemic disease: Use of a prostatic-specific membrane reverse transcription polymerase chain reaction
Su S, Heston W, Perroti M, Cookson M, Stroumbakis N, Huyrk R, Edwards E, Brander B, Coke J, Soloway S, Lewis A, Fair W. Evaluating neoadjuvant therapy effectiveness on systemic disease: Use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology 1997, 49: 95-101. PMID: 9123743, DOI: 10.1016/s0090-4295(97)00175-1.Peer-Reviewed Original ResearchConceptsProstatic specific membrane antigenAndrogen deprivation therapyNeoadjuvant androgen deprivation therapyADT groupReverse transcription-polymerase chain reactionDeprivation therapyTranscription-polymerase chain reactionControl groupProstatic cellsTumor cellsPT2 patientsPT3 patientsSystemic diseasePolymerase chain reactionEffectiveness of ADTMemorial Sloan-Kettering Cancer CenterSerum PSA valuesProstate cancer patientsChain reactionHigher positive rateProstatic epithelial cellsPT3 lesionsControl patientsExtraprostatic diseaseAdditional patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply